Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

545

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

May 31, 2026

Conditions
Presbyopia
Interventions
DRUG

0.75% phentolamine ophthalmic solution

Once daily dosing

DRUG

Placebo

Once daily dosing

Trial Locations (13)

14618

United States, Rochester

27529

United States, Garner

32779

United States, Longwood

33484

United States, Delray Beach

37072

United States, Goodlettsville

38119

United States, Memphis

45701

United States, Athens

78229

United States, San Antonio

85028

United States, Phoenix

85260

United States, Scottsdale

91204

United States, Glendale

92663

United States, Newport Beach

02888

United States, Warwick

Sponsors
All Listed Sponsors
lead

Ocuphire Pharma, Inc.

INDUSTRY

NCT06542497 - Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia | Biotech Hunter | Biotech Hunter